Loading...

FITC anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136
C57BL/6 mouse splenocytes were stained with NK1.1 (clone PK136) FITC and NKG2D PE.
  • PK136
    C57BL/6 mouse splenocytes were stained with NK1.1 (clone PK136) FITC and NKG2D PE.
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
108705 50 µg 47 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108706 500 µg 132 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  2. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  3. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  4. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  5. Calcinotto A, et al. 2018. Nat Commun. 9:4832. PubMed
  6. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  7. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  8. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  9. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  10. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  11. Bárcena C et al. 2019. EBioMedicine. 43:513-524 . PubMed
  12. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  13. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  14. Shahzad KA, et al. 2018. Drug Deliv. 25:703. PubMed
  15. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  16. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  17. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  18. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  19. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  20. Benechet AP, et al. 2019. Nature. 574:200. PubMed
  21. Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed
  22. Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
  23. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  24. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  25. Fullertona A, et al. 2013. Toxicol Appl Pharmacol. 266:317. PubMed
  26. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  27. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  28. Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed
  29. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  30. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  31. Valkenburg S, et al. 2016. Sci Rep. 6:22666. PubMed
  32. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  33. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  34. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  35. Song Y, et al. 2016. Mol Cancer Ther. 15: 2413 - 2421. PubMed
  36. Köchl R, et al. 2020. Elife. 9:00. PubMed
  37. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  38. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  39. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  40. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  41. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  42. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  43. Giampazolias E, et al. 2021. Cell. . PubMed
  44. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  45. Zaman R, et al. 2021. Immunity. :. PubMed
  46. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  47. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  48. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  49. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  50. Werner A, et al. 2021. iScience. 24:103076. PubMed
  51. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  52. Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed
  53. Wang X, et al. 2022. Elife. 11:. PubMed
  54. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  55. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  56. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  57. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  58. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  59. Lam KC, et al. 2021. Cell. 184:5338. PubMed
  60. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  61. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  62. Chung YM, et al. 2022. Am J Cancer Res. 12:1241. PubMed
  63. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  64. Wolf KG, et al. 2022. JVS Vasc Sci. 3:336. PubMed
  65. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  66. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  67. Nozaki K, et al. 2022. Nature. 606:960. PubMed
  68. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  69. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  70. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  71. Tsioti I, et al. 2023. J Neuroinflammation. 20:25. PubMed
  72. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  73. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  74. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  75. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
  76. Peng J, et al. 2023. Am J Reprod Immunol. 89:e13678. PubMed
RRID
AB_313392 (BioLegend Cat. No. 108705)
AB_313393 (BioLegend Cat. No. 108706)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 12.08.2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account